PubGene AS has together with BGI-Europe conducted several market studies using multiple techniques for investigation, including web searches, analysis of available marketing reports, analysis of annual reports from numerous stakeholders in the market and discussions with key opinion leaders. The purpose of these investigations was to obtain a better understanding of the market and market segments. We have analysed the customer categories and found that the customers of our service will first and foremost be hospitals and cancer diagnostics and treatment centers. Moreover, we have identified several factors differentiating our product/service from other suppliers in the same business space, such as competitiveness on price, geographical location, scalability and a service model with a comprehensive one-stop-shop providing full pipeline integration with existing database structures and continuous deep mining. We have developed a plan for how to develop the methods, integrating information related to biomarkers and diagnostics. We have also identified the risks with commercialization, which includes the maturation of the precision medicine market.
We have identified 5 work packages for the development plan. These will allow the project to proceed towards integrating NGS data with an existing EMR system, with the addition of data retrieval and comparison functionality to serve for clinical decision review and support. We have now also made estimations about the foreseen product launch in Q1 2019, which would include a product selection, ranging from fee-for-service to customized integration products covering the complete or individual parts of the PCMPS pipeline.